Pneumovax 23 Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The pneumovax 23 market research report is one of a series of new reports that provides pneumovax 23 market statistics, including the pneumovax 23 industry's global market size, regional shares, competitors with a pneumovax 23 market share, detailed pneumovax 23 market segments, market trends and opportunities, and any further data you may need to thrive in the pneumovax 23 industry. This pneumovax 23 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to growing urbanization, rising number of aging populations, rising prevalence of co-morbidities, increasing healthcare infrastructure investments, and increasing use of digital health platforms. Major trends in the forecast period include advancements in vaccine cold chain management, development of needle-free vaccine delivery systems, integration of artificial intelligence and machine learning, advancements in vaccine packaging technologies, and personalized vaccine delivery systems.

The growing incidence of pneumococcal diseases is expected to drive the expansion of the Pneumovax 23 market in the coming years. Pneumococcal diseases are caused by the bacterium Streptococcus pneumoniae, which can result in a range of health problems, from mild issues such as sinus infections and ear infections to more severe conditions such as pneumonia and meningitis. These can sometimes lead to hospitalization. The rising incidence of pneumococcal diseases is influenced by factors such as decreased vaccination rates during the COVID-19 pandemic, the higher vulnerability of individuals with chronic health conditions, and the resurgence of respiratory infections as social restrictions have eased. Pneumovax 23 works by immunizing individuals against 23 strains of Streptococcus pneumoniae, thereby reducing the risk of infections such as pneumonia, meningitis, and bacteremia. For example, in January 2023, the Office for National Statistics reported that in December 2022, excess deaths in England due to influenza and pneumonia were 26.2% above the usual rate. This highlights the rising burden of pneumococcal diseases and is driving the growth of the Pneumovax 23 market.

The increasing rate of urbanization is also expected to contribute to the growth of the Pneumovax 23 market. Urbanization is largely driven by factors such as industrialization, which brings better job opportunities, enhanced access to healthcare, and a higher standard of living that attracts people from rural areas. As urban populations grow, so does their access to healthcare education and awareness campaigns. This can lead to higher vaccination rates as more people understand the importance of preventing pneumococcal diseases. According to a report by the World Bank Group in April 2023, approximately 56% of the global population, or about 4.4 billion people, currently live in urban areas, with that number expected to increase, potentially doubling by 2050. This rapid urbanization is further fueling demand for vaccines such as Pneumovax 23.

The expansion of government immunization programs is another key factor expected to drive the growth of the Pneumovax 23 market. Governments at the national and local levels often implement immunization programs to prevent vaccine-preventable diseases, boost vaccination coverage, and improve public health outcomes. These initiatives may include regular vaccination schedules, special campaigns, and efforts to raise public awareness. As governments work to fill gaps in immunization, especially those caused by the COVID-19 pandemic, they are increasing access to vaccines and ensuring equitable distribution. For example, a report by the UK Parliament in March 2024 stated that in 2022, the UK had an immunization rate of 90%, placing it 32nd among the 38 OECD member countries. With a focus on improving immunization rates, these government efforts are expected to further drive the demand for Pneumovax 23.

The key company operating in the pneumovax 23 market is Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

North America was the largest region in the pneumovax 23 market in 2024. The regions covered in pneumovax 23 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumovax 23 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Pneumovax 23 is a vaccine that provides protection against 23 different strains of pneumococcal bacteria, which are responsible for severe infections such as pneumonia, meningitis, and bloodstream infections. It is primarily recommended for older adults and individuals with certain medical conditions to help prevent invasive pneumococcal diseases. The vaccine works by stimulating the immune system to recognize and fight these bacterial strains, offering long-term immunity.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations of Pneumovax 23 include the pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccine (PCV). The pneumococcal polysaccharide vaccine (PPV) is specifically designed to protect against multiple pneumococcal strains using polysaccharides from bacterial capsules. Pneumovax 23, as a widely used PPV, defends against 23 strains of pneumococcal bacteria. It is commonly administered for the prevention of pneumococcal diseases and is used in settings such as hospitals, clinics, ambulatory surgical centers, and pharmacies.

The pneumovax 23 market consists of the sales of pneumovax 23 vaccine (the primary 23-valent pneumococcal polysaccharide vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.